Peak Bio Co., Ltd.

Insmed Incorporated , Structure Therapeutics, Inc. and Merus N.V. raised more than $1.5bn combined in recent follow-on public offerings (FOPOs), taking advantage of a spike in investor interest an

Who: Akari Therapeutics/Peak Bio What: Two struggling, publicly traded biotechs will combine in an all-stock merger of equals. Why: The combined firm, which will boast a Phase III C5/LTB4 inhibit

Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been